Top

Published in:

Open Access 01-07-2017 | Review Article

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Authors: C. Shustik, I. Bence-Bruckler, R. Delage, C. J. Owen, C. L. Toze, S. Coutre

Published in: Annals of Hematology | Issue 7/2017

Abstract

Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy. However, most treated patients will relapse and require subsequent therapy. This review focuses on recent advances in the treatment of relapsed or refractory CLL. Until recently, treatment options for relapsed CLL were of limited efficacy. Retreatment with fludarabine, cyclophosphamide, and rituximab (FCR) was recommended for patients with a durable response to first-line FCR, although acquired genetic aberrations, impaired marrow reserve, and comorbidities often made this suboptimal therapy for many patients. New options include two agents targeting B cell receptor (BCR) signaling pathways (ibrutinib and idelalisib) and a B cell lymphoma-2 (BCL-2) inhibitor (venetoclax). Allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative option for younger patients with a suitable donor.

Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174CrossRefPubMed

Robak T, Dmoszynska A, Solal-Céligny P et al (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756–1765CrossRefPubMed

Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

Statistics Canada. Table 1030553: new cases and 1991 agestandardized rate for primary cancer (based on the August 2015 CCR tabulation file), by cancer type and sex, Canada, provinces and territories. Available at: http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=1030553. Accessed November 16, 2016.

Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, ESMO Guidelines Working Group (2011) Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi50–vi54PubMed

Siddon AJ, Rinder HM, Education Committee of the Academy of Clinical Laboratory Physicians and Scientists (2013) Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia. Am J Clin Pathol 139:708–712CrossRefPubMed

Döhner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916CrossRefPubMed

Nabhan C, Raca G, Wang YL (2015) Predicting prognosis in chronic lymphocytic leukemia in the contemporary era. JAMA Oncol 1:965–974CrossRefPubMed

Rossi D, Lobetti Bodoni C, Genuardi E et al (2009) Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia. Leukemia 23:1062–1072CrossRefPubMed

10.

The International CLL-IPI working group (2016) An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Onco 17:779–790CrossRef

11.

Hallek M, Cheson BD, Catovsky D, International Workshop on Chronic Lymphocytic Leukemia et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456

12.

Fischer K, Bahlo J, Fink AM et al (2016) Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127:208–215CrossRefPubMed

13.

Thompson PA, Tam CS, O’Brien SM et al (2016) Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127:303–309CrossRefPubMedPubMedCentral

14.

Tam CS, O’Brien S, Wierda W et al (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975–980CrossRefPubMedPubMedCentral

15.

Fischer K, Cramer P, Busch R et al (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30(26):3209–3216CrossRefPubMed

16.

Eichhorst B, Fink A-M, Bahlo J et al (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928–942CrossRefPubMed

17.

Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101–1110CrossRefPubMed

18.

Hillmen P, Robak T, Janssens A et al (2015) Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 385(9980):1873–1883CrossRefPubMed

19.

Robak T, Warzocha K, Babu G et al (2016) Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma 10:1–9

20.

Byrd JC, Furman RR, Coutré SE et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42CrossRefPubMedPubMedCentral

21.

Oscier D, Dearden C, Eren E et al (2012) Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol 159:541–564PubMed

22.

Dreger P, Döhner H, Ritgen M et al (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 116:2438–2447CrossRefPubMed

23.

Khouri IF, Bassett R, Poindexter N et al (2011) Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 117:4679–4688CrossRefPubMedPubMedCentral

24.

Sorror ML, Storer B, Sandmaier BM, et al. (2010) Impacts of cytogenetic abnormalities and prior alemtuzumab on outcomes of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). [abstract 2364] Blood 116:2364. Available at: http://www.bloodjournal.org/content/116/21/2364. Accessed January 2, 2016.

25.

Brown JR, Kim HT, Armand P et al (2013) Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 27:362–369CrossRefPubMed

26.

Toze CL, Dalal CB, Nevill TJ et al (2012) Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol 158:174–185CrossRefPubMed

27.

Hebenstreit K, Iacobelli S, Leiblein S et al (2014) Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia. Leuk Lymphoma 55:1274–1280CrossRefPubMed

28.

Dreger P, Corradini P, Kimby E et al (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21:12–17CrossRefPubMed

29.

Herth I, Dietrich S, Benner A et al (2014) The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann Oncol 25:200–206CrossRefPubMed

30.

Kharfan-Dabaja MA, Kumar A, Hamadani M et al (2016) Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines Committee of the American Society for blood and marrow transplantation. Biol Blood Marrow Transplant 22(12):2117–2125CrossRefPubMed

31.

Dreger P, Schetelig J, Andersen N et al (2014) Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 124:3841–3849CrossRefPubMedPubMedCentral

32.

Ryan CE, Sahaf B, Logan AC, et al. (2016) Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood 128:2899–2908

33.

Cheson BD, Byrd JC, Rai KR et al (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30:2820–2822CrossRefPubMedPubMedCentral

34.

U.S. Food and Drug Administration. FDA News Release: FDA approves Imbruvica to treat chronic lymphocytic leukemia. Silver Spring, MD: U.S. Department of Health and Human Services; 2014. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm385764.htm. Accessed August 29, 2016.

35.

U.S. Food and Drug Administration. FDA News Release: FDA expands approved use of Imbruvica for chronic lymphocytic leukemia. Silver Spring, MD: U.S. Department of Health and Human Services; 2014. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm406916.htm. Accessed August 29, 2016.

36.

Advani RH, Buggy JJ, Sharman JP et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88–94CrossRefPubMed

37.

Byrd JC, Brown JR, O’Brien S, et al; for the RESONATE Investigators (2014) Ibrutinib versus of atumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213–223

38.

Byrd JC, Furman RR, Coutré SE et al (2015) Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125:2497–2506CrossRefPubMedPubMedCentral

39.

Farooqui M, Valdez J, Soto S, Bray A, Tian X, Wiestner A. Atrial fibrillation in CLL/SLL patients on ibrutinib. [abstract 2933] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5–8, 2015; Orlando, USA. Available at: http://www.bloodjournal.org/content/126/23/2933. Accessed April 4, 2016.

40.

Shanafelt TD, Chaffee KG, Call TG, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). [abstract 2950] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5–8, 2015; Orlando, USA. Available at: https://ash.confex.com/ash/2015/webprogram/Paper82991.html. Accessed January 26, 2016. 37

41.

Leong DP, Caron F, Hillis C et al (2016) The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood 128:138–140 38 CrossRefPubMed

42.

Imbruvica (ibrutinib) product monograph. Janssen Inc. July 19, 2016.

43.

Burger JA, Tedeschi A, Barr PM et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373:2425–2437CrossRefPubMedPubMedCentral

44.

Cramer P, Chanan-Khan A, Fraser G, et al. Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial. [abstract 102] Presented at the 16th International Workshop on Chronic Lymphocytic Leukaemia; September 7–9, 2015; Sydney, Australia.

45.

Lipsky AH, Farooqui MZH, Tian X et al (2015) Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 100:1571–1578CrossRefPubMedPubMedCentral

46.

Sun C, Tian X, Lee YS et al (2015) Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 126:2213–2219CrossRefPubMedPubMedCentral

47.

Barrientos JC, O’Brien S, Brown JR, et al. Hematologic and immunologic function and patient well-being for the phase III RESONATE^™ study of ibrutinib vs ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. [abstract 4696] Presented at the 56th Annual Meeting and Exposition of the American Society of Hematology; December 6–9, 2014; San Francisco, USA. Available at: https://ash.confex.com/ash/2014/webprogram/Paper67774.html. Accessed February 24, 2016.

48.

Rogers KA, Ruppert AS, Bingman A et al (2016) Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia 30:346–350PubMed

49.

Herman SE, Gordon AL, Wagner AJ et al (2010) Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116:2078–2088CrossRefPubMedPubMedCentral

50.

Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V (2015) Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 21:1537–1542CrossRefPubMedPubMedCentral

51.

U.S. Food and Drug Administration. FDA News Release: FDA approves Zydelig for three types of blood cancers. Silver Spring, MD: U.S. Department of Health and Human Services; 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm. Accessed Sept 9, 2016.

52.

Furman RR, Sharman JP, Coutré SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997–1007CrossRefPubMedPubMedCentral

53.

Sharman JP, Coutré SE, Furman RR, et al. (2014) Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del (17p) and other adverse prognostic factors. [abstract 330] Blood 124:330. Available at: http://www.bloodjournal.org/content/124/21/330. Accessed December 14, 2015.

54.

O’Brien SM, Lamanna N, Kipps TJ et al (2015) A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood 126:2686–2694CrossRefPubMedPubMedCentral

55.

Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA (2015) Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol 39:1653–1660CrossRefPubMed

56.

Coutré SE, Barrientos JC, Brown JR et al (2015) Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 56:2779–2786CrossRefPubMedPubMedCentral

57.

Gilead Sciences Inc. Decreased overall survival and increased risk of serious infections in patients receiving ZYDELIG (idelalisib). March 21, 2016. Available at: http://zydelig.com/Content/pdf/Zydelig-Safety-Info-FINAL.pdf. Accessed April 4, 2016.

58.

Anderson MA, Deng J, Seymour JF et al (2016) The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 127:3215–3224CrossRefPubMedPubMedCentral

59.

U.S. Food and Drug Administration. FDA News Release: FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality. Silver Spring, MD: U.S. Department of Health and Human Services; 2016. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm495253.htm. Accessed Sept 9, 2016.

60.

Seymour JF, Davids MS, Pagel JM, et al. (2013) Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). [abstract 872] Blood 122:872. Available at: http://www.bloodjournal.org/content/122/21/872. Accessed December 14, 2015.

61.

Roberts A, Ma S, Brander D, et al. Venetoclax (ABT-199/GDC-0199) combined with rituximab induces deep responses in patients with relapsed/refractory chronic lymphocytic leukemia. [abstract S431] Presented at the 20th Congress of the European Hematology Association; June 11–14, 2015; Vienna, Austria. Available at: http://learningcenter.ehaweb.org/eha/2015/20th/103125/. Accessed April 4, 2016.

62.

Roberts AW, Davids MS, Pagel JM et al (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374:311–322CrossRefPubMed

63.

Stilgenbauer S, Eichhorst B, Schetelig J et al (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17:768–778CrossRefPubMed

64.

Fraser G, Cramer P, Demirkan F, et al. Ibrutinib plus bendamustine and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL): 2-year follow-up including MRD from the HELIOS study. [abstract S430] Presented at the 21st Congress of the European Hematology Association; June 9–12, 2016; Copenhagen, Denmark. Available at: http://learningcenter.ehaweb.org/eha/2016/21st/135186/. Accessed July 19, 2016.

65.

Sorenson S, Tam C, Diels J et al Indirect comparison of ibrutinib versus idelalisib plus ofatumumab in patients with previously treated chronic lymphocytic leukemia [poster]. XVI International Workshop on Chronic Lymphocytic Leukaemia; September 7–9, 2015; Sydney. Australia

66.

Maddocks KJ, Ruppert AS, Lozanski G et al (2015) Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1:80–87CrossRefPubMedPubMedCentral

67.

O’Brien SM, Byrd JC, Hillmenn P, et al. Outcomes with ibrutinib by line of therapy in patients with CLL: analyses from phase III data. [abstract 7520] Presented at the 2016 Annual Meeting of the American Society of Clinical Oncology; June 3–7, 2016; Chicago, USA. Available at: http://meetinglibrary.asco.org/content/164543-176. Accessed August 29, 2016.

68.

O’Brien S, Furman RR, Coutre SE et al (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15:48–58CrossRefPubMed

69.

Woyach JA, Furman RR, Liu TM et al (2014) Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286–2294CrossRefPubMedPubMedCentral

70.

Mato A, Nabhan C, Barr PM, et al. Favorable outcomes in CLL pts with alternate kinase inhibitors following ibrutinib or idelalisib discontinuation: results from a large multi-center study. [abstract 719] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5–8, 2015; Orlando, USA. Available at: https://ash.confex.com/ash/2015/webprogram/Paper80707.html. Accessed January 26, 2016.

71.

Jones J, Mato AR, Coutre S, et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy. [abstract 715] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5–8, 2015; Orlando, USA. Available at: https://ash.confex.com/ash/2015/webprogram/Paper81347.html. Accessed January 1, 2016.

72.

U.S. Food and Drug Administration. FDA statement: FDA halts clinical trial of drug Revlimid (lenalidomide) for chronic lymphocytic leukemia due to safety concerns. Silver Spring, MD: U.S. Department of Health and Human Services; 2013. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm361444.htm. Accessed January 2, 2016.

73.

Byrd JC, Harrington B, O’Brien S et al (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374:323–332CrossRefPubMed

74.

Chanan-Khan A, Cramer P, Demirkan F et al (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17:200–211CrossRefPubMed

75.

Zelenetz AD, Robak T, Coiffier B, et al. Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study. [abstract LBA-5] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5–8, 2015; Orlando, USA. Available at: https://ash.confex.com/ash/2015/webprogram/Paper87420.html. Accessed February 24, 2016.

76.

Jones JA, Robak T, Wach M, et al. Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL). [abstract 7515] Presented at the 2016 Annual Meeting of the American Society of Clinical Oncology; June 3–7, 2016; Chicago, USA. Available at: http://meetinglibrary.asco.org/content/163777-176. Accessed November 16, 2016.

77.

Barr PM, Saylors GB, Spurgeon SE et al (2016) Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 127:2411–2415CrossRefPubMedPubMedCentral

78.

Davids MS, Kim HT, Bsat J, et al. Preliminary results of a phase II study of ibrutinib in combination with FCR (iFCR) in previously untreated, younger patients with CLL. [abstract P210] Presented at the 21st Congress of the European Hematology Association; June 9–12, 2016; Copenhagen, Denmark. Available at: http://learningcenter.ehaweb.org/eha/2016/21st/133198/. Accessed August 29, 2016.

79.

Oppermann S, Ylanko J, Shi Y et al (2016) High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood 128:934–947

Title: Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Authors: C. Shustik
I. Bence-Bruckler
R. Delage
C. J. Owen
C. L. Toze
S. Coutre
Publication date: 01-07-2017
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 7/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-017-2982-1

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2017

Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus

Pyogenic brain abscesses treated with antibiotics in a patient with hemophagocytic lymphohistiocytosis on HLH-94 protocol

Peripheral blood lymphocyte/monocyte ratio following completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma: methodological issues to avoid misinterpretation

Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage